| Pharmaceutical amorphous nanoparticles R Jog, DJ Burgess Journal of pharmaceutical sciences 106 (1), 39-65, 2017 | 160 | 2017 |
| Development of Level A in vitro-in vivo correlations for peptide loaded PLGA microspheres JV Andhariya, R Jog, J Shen, S Choi, Y Wang, Y Zou, DJ Burgess Journal of controlled release 308, 1-13, 2019 | 66 | 2019 |
| In vitro-in vivo correlation of parenteral PLGA microspheres: Effect of variable burst release JV Andhariya, R Jog, J Shen, S Choi, Y Wang, Y Zou, DJ Burgess Journal of controlled release 314, 25-37, 2019 | 51 | 2019 |
| Solid state drug-polymer miscibility studies using the model drug ABT-102 R Jog, R Gokhale, DJ Burgess International journal of pharmaceutics 509 (1-2), 285-295, 2016 | 42 | 2016 |
| In Vitro and In Vivo Performance of Different Sized Spray‐Dried Crystalline Itraconazole S Kumar, R Jog, J Shen, B Zolnik, N Sadrieh, DJ Burgess Journal of pharmaceutical sciences 104 (9), 3018-3028, 2015 | 39 | 2015 |
| In vitro release testing method development for ophthalmic ointments Q Bao, J Shen, R Jog, C Zhang, B Newman, Y Wang, S Choi, DJ Burgess International journal of pharmaceutics 526 (1-2), 145-156, 2017 | 37 | 2017 |
| Physicochemical attributes and dissolution testing of ophthalmic ointments Q Bao, R Jog, J Shen, B Newman, Y Wang, S Choi, DJ Burgess International journal of pharmaceutics 523 (1), 310-319, 2017 | 35 | 2017 |
| Comprehensive quality by design approach for stable nanocrystalline drug products R Jog, DJ Burgess International journal of pharmaceutics 564, 426-460, 2019 | 30 | 2019 |
| Formulation design and evaluation of amorphous ABT-102 nanoparticles R Jog, S Kumar, J Shen, N Jugade, DCT Tan, R Gokhale, DJ Burgess International journal of pharmaceutics 498 (1-2), 153-169, 2016 | 28 | 2016 |
| Formulation and performance of danazol nano-crystalline suspensions and spray dried powders S Kumar, R Jog, J Shen, B Zolnik, N Sadrieh, DJ Burgess Pharmaceutical research 32, 1694-1703, 2015 | 24 | 2015 |
| Formulation and evaluation of itraconazole liposomes for Hedgehog pathway inhibition JR Pace, R Jog, DJ Burgess, MK Hadden Journal of liposome research 30 (3), 305-311, 2020 | 20 | 2020 |
| Formulation design space for stable, pH sensitive crystalline nifedipine nanoparticles R Jog, K Unachukwu, DJ Burgess International Journal of pharmaceutics 514 (1), 81-92, 2016 | 19 | 2016 |
| Pectin microparticles for peptide delivery: Optimization of spray drying processing T Li, B Wan, R Jog, A Costa, DJ Burgess International Journal of Pharmaceutics 613, 121384, 2022 | 13 | 2022 |
| Nanoamorphous drug products–Design and development R Jog, DJ Burgess International journal of pharmaceutics 553 (1-2), 238-260, 2018 | 12 | 2018 |
| Excipients used in oral nanocarrier-based formulations R Jog, DJ Burgess Fundamentals of Nanoparticles, 279-342, 2018 | 4 | 2018 |
| Effect of counterion on the solid state photodegradation behavior of prazosin salts L Kumar, R Jog, S Singh, A Bansal AAPS PharmSciTech 14, 757-763, 2013 | 4 | 2013 |
| Use of Apparatus 4 in Dissolution Testing, Including Sparingly and Poorly Soluble Drugs R Jog, GN Grove, DJ Burgess Poorly Soluble Drugs, 279-324, 2017 | 2 | 2017 |
| Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats S Khare, R Jog, A Bright, DJ Burgess, SK Chakder, K Gokulan Nanotoxicology 17 (10), 583-603, 2023 | | 2023 |
| Characterization of Encapsulated Liposomal Irinotecan JM Noble, L Chen, R Jog, D Kozak, J Zheng Microscopy and Microanalysis 25 (S2), 1274-1275, 2019 | | 2019 |
| Formulation Design and Evaluation of Amorphous and Crystalline Nanoparticles of BCS Class II and II/IV Drugs R Jog | | 2018 |
Diane J. BurgessUniversity of Connecticut Board of Trustees Distinguished Professor of PharmaceuticsVerified email at uconn.edu
